{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:15:44Z","timestamp":1792401344355,"version":"4.4.0"},"reference-count":208,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.pharmthera.2018.08.015","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T22:41:04Z","timestamp":1535150464000},"page":"132-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts"],"prefix":"10.1016","volume":"194","author":[{"given":"Andreas L.","family":"Birkenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dworak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Burnstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.08.015_bb0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME Study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0015","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2174\/138161209787582101","article-title":"The heart metabolism: Pathophysiological aspects in ischaemia and heart failure","volume":"15","author":"Abozguia","year":"2009","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0020","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0026-895X(25)10180-6","article-title":"A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release","volume":"45","author":"Akbar","year":"1994","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1527-5299.2007.06047.x","article-title":"Effect of chronic sustained-release dipyridamole on myocardial blood flow and left ventricular function in patients with ischemic cardiomyopathy","volume":"13","author":"Akhtar","year":"2007","journal-title":"Congestive Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0030","first-page":"H742","article-title":"Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts","volume":"267","author":"Allard","year":"1994","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00000441-200104000-00003","article-title":"Obesity cardiomyopathy: Pathophysiology and evolution of the clinical syndrome","volume":"321","author":"Alpert","year":"2001","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0040","first-page":"213","article-title":"Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group","volume":"23","author":"Amato","year":"1997","journal-title":"Diabetes & Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0045","author":"American Heart Association"},{"issue":"9","key":"10.1016\/j.pharmthera.2018.08.015_bb8005","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2337\/dc18-su09","article-title":"Updates to the Standards of Medical Care in Diabetes-2018","volume":"41","author":"Association American Diabetes","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0050","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0055","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0060","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.ATV.0000015598.86369.04","article-title":"Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis","volume":"22","author":"Barbier","year":"2002","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000433","article-title":"Taking diabetes to heart\u2014Deregulation of myocardial lipid metabolism in diabetic cardiomyopathy","volume":"2","author":"Bayeva","year":"2013","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0070","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/hrt.2009.190256","article-title":"Modification of myocardial substrate utilisation: A new therapeutic paradigm in cardiovascular disease","volume":"96","author":"Beadle","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jchf.2014.09.009","article-title":"Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy","volume":"3","author":"Beadle","year":"2015","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0080","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","article-title":"Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure","volume":"133","author":"Bedi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0085","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: A report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0090","series-title":"Biochemistry","article-title":"The citric acid cycle","author":"Berg","year":"2002"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0095","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/(SICI)1522-2683(19990701)20:10<2059::AID-ELPS2059>3.0.CO;2-T","article-title":"Increase in expression of P2X1 receptors in the atria of patients suffering from dilated cardiomyopathy","volume":"20","author":"Berry","year":"1999","journal-title":"Electrophoresis"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0100","article-title":"Metabolic remodelling in heart failure","author":"Bertero","year":"2018","journal-title":"Nature Reviews Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0105","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1161\/HYPERTENSIONAHA.110.165159","article-title":"Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition","volume":"57","author":"Birkenfeld","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043238","article-title":"Atrial natriuretic peptide and adiponectin interactions in man","volume":"7","author":"Birkenfeld","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0115","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1210\/jc.2004-1953","article-title":"Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans","volume":"90","author":"Birkenfeld","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0120","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1210\/jc.2006-1084","article-title":"Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation","volume":"91","author":"Birkenfeld","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0125","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.2337\/db08-0649","article-title":"Atrial natriuretic peptide induces postprandial lipid oxidation in humans","volume":"57","author":"Birkenfeld","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0130","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0135","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.CIR.87.3.972","article-title":"Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation","volume":"87","author":"Broderick","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/pr.58.1.5","article-title":"Pathophysiology and therapeutic potential of purinergic signaling","volume":"58","author":"Burnstock","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1152\/physrev.00043.2006","article-title":"Physiology and pathophysiology of purinergic neurotransmission","volume":"87","author":"Burnstock","year":"2007","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0150","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00018-007-6497-0","article-title":"Purine and pyrimidine receptors","volume":"64","author":"Burnstock","year":"2007","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0155","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/CIRCRESAHA.116.309726","article-title":"Purinergic Signaling in the Cardiovascular System","volume":"120","author":"Burnstock","year":"2017","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0074-7696(04)40002-3","article-title":"Cellular distribution and functions of P2 receptor subtypes in different systems","volume":"240","author":"Burnstock","year":"2004","journal-title":"International Review of Cytology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11302-014-9436-1","article-title":"Cardiac purinergic signalling in health and disease","volume":"11","author":"Burnstock","year":"2015","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0170","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.113.008029","article-title":"Purinergic signaling and blood vessels in health and disease","volume":"66","author":"Burnstock","year":"2014","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0175","first-page":"149","article-title":"Ketoacids? Good medicine?","volume":"114","author":"Cahill","year":"2003","journal-title":"Transactions of the American Clinical and Climatological Association"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bbalip.2005.03.005","article-title":"Fatty acid metabolism is enhanced in type 2 diabetic hearts","volume":"1734","author":"Carley","year":"2005","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0185","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0002-8703(62)90305-8","article-title":"Myocardial fat infiltration","volume":"63","author":"Carpenter","year":"1962","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0190","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0195","doi-asserted-by":"crossref","first-page":"H1538","DOI":"10.1152\/ajpheart.00281.2004","article-title":"Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation","volume":"287","author":"Chandler","year":"2004","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0200","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/1440-1681.12616","article-title":"VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model","volume":"43","author":"Chuo","year":"2016","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0205","doi-asserted-by":"crossref","first-page":"H2009","DOI":"10.1152\/ajpheart.00522.2007","article-title":"Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance","volume":"293","author":"Cooper","year":"2007","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0210","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cardfail.2008.08.010","article-title":"The PROTECT pilot study: A randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment","volume":"14","author":"Cotter","year":"2008","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0215","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0220","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/01.CIR.99.4.578","article-title":"Glucose for the heart","volume":"99","author":"Depre","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0225","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/CIRCULATIONAHA.108.803916","article-title":"Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus","volume":"119","author":"van der Meer","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0230","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: Nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0235","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.1994.tb04276.x","article-title":"Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group","volume":"37","author":"Detry","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0240","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11897-017-0347-7","article-title":"Targeting mitochondrial calcium handling and reactive oxygen species in heart failure","volume":"14","author":"Dietl","year":"2017","journal-title":"Current Heart Failure Reports"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0245","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jacc.2014.04.083","article-title":"Metabolic impairment in heart failure: The myocardial and systemic perspective","volume":"64","author":"Doehner","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0250","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/cvr\/cvp414","article-title":"Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload","volume":"86","author":"Doenst","year":"2010","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0255","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1096\/fasebj.12.15.1785","article-title":"Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor","volume":"12","author":"Dougherty","year":"1998","journal-title":"FASEB Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0260","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/0735-1097(94)90114-7","article-title":"Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study","volume":"24","author":"Eichhorn","year":"1994","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","author":"Emerging Risk Factors Collaboration","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0270","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1172\/JCI64526","article-title":"Natriuretic peptides enhance the oxidative capacity of human skeletal muscle","volume":"122","author":"Engeli","year":"2012","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0275","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/HYPERTENSIONAHA.117.10224","article-title":"Effect of sacubitril\/valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension","volume":"71","author":"Engeli","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0280","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0285","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: A \"thrifty substrate\" hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0290","first-page":"11","article-title":"Cardiac metabolism in the diabetic patient","volume":"46","author":"Feuvray","year":"2010","journal-title":"Heart and Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0295","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/01.CIR.87.3.900","article-title":"Adenosine alters glucose use during ischemia and reperfusion in isolated rat hearts","volume":"87","author":"Finegan","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0300","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1210\/jcem-65-2-331","article-title":"Glomerular filtration rate is increased in man by the infusion of both D,L-3-hydroxybutyric acid and sodium D,L-3-hydroxybutyrate","volume":"65","author":"Fioretto","year":"1987","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0305","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehi816","article-title":"Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine\/adenosine triphosphate ratio in patients with heart failure","volume":"27","author":"Fragasso","year":"2006","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-8703(03)00415-0","article-title":"Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy","volume":"146","author":"Fragasso","year":"2003","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0315","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.bjp.0702765","article-title":"Alteration of glycogen and glucose metabolism in ischaemic and post-ischaemic working rat hearts by adenosine A1 receptor stimulation","volume":"128","author":"Fraser","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0320","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0325","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1161\/CIRCULATIONAHA.106.620211","article-title":"Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function","volume":"114","author":"Funakoshi","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0330","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/01.CIR.95.6.1363","article-title":"Plasma adenosine levels increase in patients with chronic heart failure","volume":"95","author":"Funaya","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11010-006-2518-9","article-title":"Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts","volume":"283","author":"Gambert","year":"2006","journal-title":"Molecular and Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0340","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.109.916072","article-title":"Adenosine A1 receptor antagonists at a fork in the road","volume":"2","author":"Givertz","year":"2009","journal-title":"Circulation. Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0345","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jacc.2007.07.019","article-title":"The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance","volume":"50","author":"Givertz","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0350","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2012.04.006","article-title":"Lipid metabolism and toxicity in the heart","volume":"15","author":"Goldberg","year":"2012","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0355","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0360","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005066","article-title":"Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: A positron emission tomography study","volume":"6","author":"Gormsen","year":"2017","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0365","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0091270010375957","article-title":"Effects of BG9928, an adenosine A(1) receptor antagonist, in patients with congestive heart failure","volume":"51","author":"Gottlieb","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0370","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/00004872-200309000-00027","article-title":"Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study","volume":"21","author":"Grassi","year":"2003","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0375","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10741-015-9522-7","article-title":"Partial adenosine A1 receptor agonism: A potential new therapeutic strategy for heart failure","volume":"21","author":"Greene","year":"2016","journal-title":"Heart Failure Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0380","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0385","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study","volume":"342","author":"Gress","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0390","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2337\/dc07-1768","article-title":"Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Blood Pressure Lowering Arm and the relative influence of antihypertensive medication","volume":"31","author":"Gupta","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0395","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11154-016-9345-4","article-title":"The metabolic vascular syndrome - guide to an individualized treatment","volume":"17","author":"Hanefeld","year":"2016","journal-title":"Reviews in Endocrine & Metabolic Disorders"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0400","first-page":"E746","article-title":"Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia","volume":"270","author":"Hasselbalch","year":"1996","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0405","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1152\/physrev.1994.74.4.993","article-title":"Molecular physiology of sodium-glucose cotransporters","volume":"74","author":"Hediger","year":"1994","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0410","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ejhf.678","article-title":"Metabolic support for the heart: Complementary therapy for heart failure?","volume":"18","author":"Heggermont","year":"2016","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0415","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/CS20060307","article-title":"A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study","volume":"113","author":"Holubarsch","year":"2007","journal-title":"Clinical Science (London, England: 1979)"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0420","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ehf2.12003","article-title":"The late sodium current in heart failure: Pathophysiology and clinical relevance","volume":"1","author":"Horvath","year":"2014","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0425","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0024-3205(99)00353-7","article-title":"Increase in cardiac P2X1-and P2Y2-receptor mRNA levels in congestive heart failure","volume":"65","author":"Hou","year":"1999","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0430","doi-asserted-by":"crossref","first-page":"H1750","DOI":"10.1152\/ajpheart.01051.2001","article-title":"Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training","volume":"283","author":"Iemitsu","year":"2002","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0435","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.2174\/1381612811319270003","article-title":"Cardiac dysfunction and oxidative stress in the metabolic syndrome: An update on antioxidant therapies","volume":"19","author":"Ilkun","year":"2013","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0440","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00004872-199604000-00012","article-title":"Differential effect of chronic treatment with beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study","volume":"14","author":"Jacob","year":"1996","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0445","first-page":"533","article-title":"Altered systemic ketone body metabolism in advanced heart failure","volume":"38","author":"Janardhan","year":"2011","journal-title":"Texas Heart Institute Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0450","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/01.hjh.0000242405.68461.84","article-title":"Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation","volume":"24","author":"Janke","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0455","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/ndt\/gfm049","article-title":"Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy","volume":"22","author":"Jin","year":"2007","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2018.08.015_bb0460","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cpt.455","article-title":"Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension","volume":"101","author":"Jordan","year":"2017","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0465","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cpt.455","article-title":"Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension","volume":"101","author":"Jordan","year":"2017","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0470","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089201","article-title":"Atrial natriuretic peptide and type 2 diabetes development\u2014Biomarker and genotype association study","volume":"9","author":"Jujic","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0480","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0485","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10741-012-9360-9","article-title":"A \"PET\" area of interest: Myocardial metabolism in human systolic heart failure","volume":"18","author":"Kadkhodayan","year":"2013","journal-title":"Heart Failure Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0490","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1365-2362.1999.00468.x","article-title":"Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy","volume":"29","author":"Kalsi","year":"1999","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0495","series-title":"Heart physiology and pathophysiology","author":"Kantor","year":"2001"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0500","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0505","doi-asserted-by":"crossref","first-page":"10436","DOI":"10.1073\/pnas.1601650113","article-title":"Oncometabolite d-2-hydroxyglutarate impairs alpha-ketoglutarate dehydrogenase and contractile function in rodent heart","volume":"113","author":"Karlstaedt","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0510","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002423","article-title":"Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events","volume":"4","author":"Kerkela","year":"2015","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0515","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1755-5922.12183","article-title":"Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction","volume":"34","author":"Kobalava","year":"2016","journal-title":"Cardiovascular Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0520","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/CIRCULATIONAHA.116.021230","article-title":"Ketones step to the plate: A game changer for metabolic remodeling in heart failure?","volume":"133","author":"Kolwicz","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0525","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1161\/CIRCRESAHA.113.302095","article-title":"Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes","volume":"113","author":"Kolwicz","year":"2013","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0530","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1152\/physrev.00022.2015","article-title":"Molecular physiology of membrane guanylyl cyclase receptors","volume":"96","author":"Kuhn","year":"2016","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0535","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.coph.2006.10.008","article-title":"Anti-anginal effects of partial fatty acid oxidation inhibitors","volume":"7","author":"Lam","year":"2007","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0540","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0545","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1161\/CIRCULATIONAHA.105.551457","article-title":"Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment","volume":"112","author":"Lee","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0550","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.amjcard.2017.05.014","article-title":"Diabetes mellitus and heart failure","volume":"120","author":"Lehrke","year":"2017","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0555","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1073\/pnas.95.12.6995","article-title":"A physiological role of the adenosine A3 receptor: Sustained cardioprotection","volume":"95","author":"Liang","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0560","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1161\/01.CIR.0000034049.61181.F3","article-title":"Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice","volume":"106","author":"Liao","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0565","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0570","doi-asserted-by":"crossref","first-page":"d1309","DOI":"10.1136\/bmj.d1309","article-title":"Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studies","volume":"342","author":"Loke","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0575","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0735-1097(96)00214-8","article-title":"Blood ketone bodies in congestive heart failure","volume":"28","author":"Lommi","year":"1996","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0580","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0585","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0735-1097(99)00418-0","article-title":"Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial","volume":"34","author":"Mahaffey","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0590","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2012.12.002","article-title":"RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: The RALI-DHF proof-of-concept study","volume":"1","author":"Maier","year":"2013","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0595","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0600","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0605","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0610","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0615","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.93.1.135","article-title":"Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts","volume":"93","author":"McCormack","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0620","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/hmg\/ddm084","article-title":"Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations","volume":"16","author":"Meirhaeghe","year":"2007","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0625","doi-asserted-by":"crossref","first-page":"E1049","DOI":"10.1152\/ajpendo.00560.2009","article-title":"Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats","volume":"298","author":"Menard","year":"2010","journal-title":"American Journal of Physiology - Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0630","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.2337\/db09-0393","article-title":"Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity","volume":"58","author":"Miyashita","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0635","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","article-title":"Aldosterone production is activated in failing ventricle in humans","volume":"103","author":"Mizuno","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0640","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2013.07.010","article-title":"Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure","volume":"63","author":"Mori","year":"2013","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0645","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14728222.2016.1254198","article-title":"Targeting cardiac natriuretic peptides in the therapy of diabetes and obesity","volume":"20","author":"Moro","year":"2016","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0650","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0655","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0660","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1161\/01.CIR.0000143072.36782.51","article-title":"Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart","volume":"110","author":"Nakamura","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0665","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1161\/01.HYP.0000144292.69599.0c","article-title":"Mechanisms for increased glycolysis in the hypertrophied rat heart","volume":"44","author":"Nascimben","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0670","series-title":"The effect of acadesine on reducing cardiovascular and cerebrovascular adverse events in Coronary Artery Bypass Graft (CABG) surgery (Study P05633 AM1) (TERMINATED) (RED-CABG)","author":"NCT00872001","year":"2018"},{"issue":"7","key":"10.1016\/j.pharmthera.2018.08.015_bb0675","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0680","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014An engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0685","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001250051341","article-title":"New insights into sympathetic regulation of glucose and fat metabolism","volume":"43","author":"Nonogaki","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0690","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0695","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/08037050510034185","article-title":"Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy","volume":"14","author":"Olsen","year":"2005","journal-title":"Blood Pressure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0700","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/01.CIR.0000023531.22727.C1","article-title":"Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure","volume":"106","author":"Osorio","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0705","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s00125-007-0735-8","article-title":"Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification","volume":"50","author":"Ouwens","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0710","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0715","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0720","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0725","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1054\/jcaf.2002.130238","article-title":"Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure","volume":"8","author":"Podbregar","year":"2002","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0730","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0735","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/CIRCRESAHA.108.189951","article-title":"Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: Attenuating upregulated anaplerosis in hypertrophy","volume":"104","author":"Pound","year":"2009","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0740","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/bph.13339","article-title":"Adenosine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to alpha1 -adrenoceptor stimulation in vivo","volume":"173","author":"Puhl","year":"2016","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0745","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0031-6997(24)01373-5","article-title":"Receptors for purines and pyrimidines","volume":"50","author":"Ralevic","year":"1998","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0750","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","article-title":"The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus","volume":"1","author":"Randle","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0755","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1042\/bj0930652","article-title":"Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles","volume":"93","author":"Randle","year":"1964","journal-title":"Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0760","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/hc4901.100526","article-title":"Metabolic gene expression in fetal and failing human heart","volume":"104","author":"Razeghi","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0765","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0770","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2174\/138161208786071317","article-title":"Cardiac metabolism in myocardial ischemia","volume":"14","author":"Rosano","year":"2008","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0775","first-page":"177","article-title":"Metabolic approach to heart failure: The role of metabolic modulators","volume":"67","author":"Rosano","year":"2015","journal-title":"The Journal of the Egyptian Public Health Association"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0780","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0008-6363(01)00393-5","article-title":"Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism","volume":"52","author":"Rosenblatt-Velin","year":"2001","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0785","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jacc.2005.02.061","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II)","volume":"45","author":"Ross","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0790","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1152\/physiolgenomics.00054.2014","article-title":"Dynamic gene expression patterns in animal models of early and late heart failure reveal biphasic-bidirectional transcriptional activation of signaling pathways","volume":"46","author":"Rowell","year":"2014","journal-title":"Physiological Genomics"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0795","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0800","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/sj.bjp.0703741","article-title":"Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure","volume":"131","author":"Rupp","year":"2000","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0805","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1291\/hypres.30.913","article-title":"Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: A prospective open-randomized study","volume":"30","author":"Sanada","year":"2007","journal-title":"Hypertension Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0810","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1096\/fasebj.9.8.7768357","article-title":"Insulin, ketone bodies, and mitochondrial energy transduction","volume":"9","author":"Sato","year":"1995","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0815","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.04.007","article-title":"Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome","volume":"144","author":"Schlueter","year":"2014","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0820","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.molmet.2014.07.010","article-title":"Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling","volume":"3","author":"Schugar","year":"2014","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0825","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","article-title":"Lipid use and misuse by the heart","volume":"118","author":"Schulze","year":"2016","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0830","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1139\/y06-007","article-title":"Adenosine A1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase","volume":"84","author":"Schutte","year":"2006","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0835","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0840","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1096\/fasebj.14.10.1345","article-title":"Natriuretic peptides: A new lipolytic pathway in human adipocytes","volume":"14","author":"Sengenes","year":"2000","journal-title":"FASEB Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0845","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fca.14.62","article-title":"Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome","volume":"10","author":"Singh","year":"2014","journal-title":"Future Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0850","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/CIRCULATIONAHA.106.668665","article-title":"Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts","volume":"115","author":"Sorokina","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0855","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2008.03.006","article-title":"Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts\u2014Role of late sodium current and intracellular ion accumulation","volume":"45","author":"Sossalla","year":"2008","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0860","first-page":"22","article-title":"Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study","volume":"41","author":"Sourgens","year":"2003","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0865","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ijo.2010.227","article-title":"Neprilysin, obesity and the metabolic syndrome","volume":"35","author":"Standeven","year":"2011","journal-title":"International Journal of Obesity (2005)"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0870","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0008-6363(96)00245-3","article-title":"Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions","volume":"33","author":"Stanley","year":"1997","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0875","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","article-title":"Myocardial substrate metabolism in the normal and failing heart","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0880","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/0976-9234.177076","article-title":"Dipyridamole in heart failure due to dilated cardiomyopathy: A pilot study","volume":"7","author":"Stea","year":"2016","journal-title":"Journal of Pharmaceutical Negative Results"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0885","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.115.020226","article-title":"Catabolic defect of branched-chain amino acids promotes heart failure","volume":"133","author":"Sun","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0890","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0735-1097(97)00185-X","article-title":"Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure","volume":"30","author":"Swan","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0895","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/en.2007-1646","article-title":"Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob\/ob) mouse hearts","volume":"149","author":"Tabbi-Anneni","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0900","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0146-2806(94)90008-6","article-title":"Energy metabolism of the heart: From basic concepts to clinical applications","volume":"19","author":"Taegtmeyer","year":"1994","journal-title":"Current Problems in Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0905","first-page":"265","article-title":"Failing Heart and Starving Brain - Ketone Bodies to the Rescue","author":"Taegtmeyer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0910","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1161\/RES.0000000000000097","article-title":"Assessing cardiac metabolism: A scientific statement from the American Heart Association","volume":"118","author":"Taegtmeyer","year":"2016","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0915","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jjcc.2016.10.019","article-title":"Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology","volume":"69","author":"Tanaka","year":"2017","journal-title":"Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0920","first-page":"55","article-title":"An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure","volume":"42","author":"Taylor","year":"2001","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0925","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11906-006-0024-9","article-title":"Deranged energy substrate metabolism in the failing heart","volume":"8","author":"Tian","year":"2006","journal-title":"Current Hypertension Reports"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0930","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1136\/hrt.2011.224451","article-title":"Myocardial steatosis, cardiac remodelling and fitness in insulin-sensitive and insulin-resistant obese women","volume":"97","author":"Utz","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0935","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejheart.2008.01.010","article-title":"Adenosine and kidney function: Potential implications in patients with heart failure","volume":"10","author":"Vallon","year":"2008","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0940","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0945","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11906-016-0626-9","article-title":"Aldosterone production and signaling dysregulation in obesity","volume":"18","author":"Vecchiola","year":"2016","journal-title":"Current Hypertension Reports"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0950","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.2337\/db11-1466","article-title":"B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men","volume":"61","author":"Vila","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0955","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/00365519109104571","article-title":"The independent effect of ketone bodies on forearm glucose metabolism in normal man","volume":"51","author":"Walker","year":"1991","journal-title":"Scandinavian Journal of Clinical and Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0960","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/01.CIR.103.20.2441","article-title":"Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure","volume":"103","author":"Wallhaus","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0965","first-page":"H2420","article-title":"Mechanism of the negative inotropic effect of adenosine in guinea pig atrial myocytes","volume":"267","author":"Wang","year":"1994","journal-title":"The American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0970","doi-asserted-by":"crossref","first-page":"H1160","DOI":"10.1152\/ajpheart.00114.2016","article-title":"Defective branched chain amino acid catabolism contributes to cardiac dysfunction and remodeling following myocardial infarction","volume":"311","author":"Wang","year":"2016","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0975","first-page":"297","article-title":"Metabolic Origins of Heart Failure","volume":"2","author":"Wende","year":"2017","journal-title":"JACC: Basic to Translational Science"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0980","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.biochem.70.1.341","article-title":"Peroxisome proliferator-activated receptor gamma and metabolic disease","volume":"70","author":"Willson","year":"2001","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0985","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1172\/JCI114616","article-title":"Effects of acute hyperglycemia on myocardial glycolytic activity in humans","volume":"85","author":"Wisneski","year":"1990","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0990","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jacc.2007.10.021","article-title":"Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options","volume":"51","author":"Witteles","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb0995","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1440-1681.2009.05300.x","article-title":"Adenosine A1 receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiomyocytes","volume":"37","author":"Xiang","year":"2010","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb1000","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1253\/circj.CJ-09-0371","article-title":"Effect of carperitide on plasma adiponectin levels in acute decompensated heart failure patients with diabetes mellitus","volume":"73","author":"Yamaji","year":"2009","journal-title":"Circulation Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb1005","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1210\/jcem.87.8.8731","article-title":"Expression of aldosterone synthase gene in failing human heart: Quantitative analysis using modified real-time polymerase chain reaction","volume":"87","author":"Yoshimura","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb1010","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.HYP.0000190041.61737.fd","article-title":"Adenosine-stimulated atrial natriuretic peptide release through A1 receptor subtype","volume":"46","author":"Yuan","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb1015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb1020","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1096\/fasebj.10.11.8836044","article-title":"Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir","volume":"10","author":"Zarain-Herzberg","year":"1996","journal-title":"FASEB Journal"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb1025","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1073\/pnas.0501744102","article-title":"Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention","volume":"102","author":"Zhang","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb1030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12967-016-0849-1","article-title":"Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy","volume":"14","author":"Zhang","year":"2016","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.015_bb1035","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New England Journal of Medicine"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T11:12:26Z","timestamp":1751800346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818301530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":208,"alternative-id":["S0163725818301530"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.08.015","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}